ARCUTIS BIOTHERAPEUTICS, INC. Financing Cash Flow
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Financing Cash Flow of $3.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.99M, a 44.20% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.07M, a 170.13% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.72M.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.48M, a 274.62% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $6.97M, a 89.47% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $66.20M, a 34.66% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $101.32M, a 66.43% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $301.80M, a 7.04% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.06M 10-Q · filed 2026-08-05 | $6.78M derived: sum of 3 quarters · filed 2026-08-05 | $8.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-06 | $4.79M derived: sum of 2 quarters · filed 2026-05-06 | $6.26M derived: sum of 3 quarters · filed 2026-05-06 | $7.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.20M derived: sum of 2 quarters · filed 2026-02-25 | $6.58M derived: sum of 3 quarters · filed 2026-08-05 | $6.97M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.86M derived: sum of 2 quarters · filed 2026-08-05 | $3.25M 10-Q · filed 2025-10-28 | -$94.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.77M 10-Q · filed 2026-08-05 | -$95.64M derived: sum of 3 quarters · filed 2026-08-05 | -$95.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $395.00K 10-Q · filed 2026-05-06 | -$97.02M derived: sum of 2 quarters · filed 2026-05-06 | -$96.62M derived: sum of 3 quarters · filed 2026-05-06 | -$95.17M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$97.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$97.02M derived: sum of 2 quarters · filed 2026-02-25 | -$95.56M derived: sum of 3 quarters · filed 2026-02-25 | $66.20M 10-K · filed 2026-02-25 |
| 2024-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.85M derived: sum of 2 quarters · filed 2025-10-28 | $163.61M 10-Q · filed 2025-10-28 | $262.90M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $163.22M 10-Q · filed 2025-08-06 | $262.51M derived: sum of 3 quarters · filed 2026-02-25 | $263.38M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $161.76M 10-Q · filed 2025-05-06 | $261.05M derived: sum of 2 quarters · filed 2026-02-25 | $261.92M derived: sum of 3 quarters · filed 2026-02-25 | $262.99M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $99.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $100.16M derived: sum of 2 quarters · filed 2026-02-25 | $101.22M derived: sum of 3 quarters · filed 2026-02-25 | $101.32M 10-K · filed 2026-02-25 |
| 2023-09-30 | $867.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.93M derived: sum of 2 quarters · filed 2024-11-06 | $2.03M 10-Q · filed 2024-11-06 | $3.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.17M 10-Q · filed 2024-08-14 | $2.13M derived: sum of 3 quarters · filed 2025-02-25 | $287.12M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-14 | $1.06M derived: sum of 2 quarters · filed 2025-02-25 | $286.05M derived: sum of 3 quarters · filed 2025-02-25 | $287.18M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $962.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $285.95M derived: sum of 2 quarters · filed 2025-02-25 | $287.08M derived: sum of 3 quarters · filed 2025-02-25 | $301.80M 10-K · filed 2025-02-25 |
| 2022-09-30 | $284.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $286.12M derived: sum of 2 quarters · filed 2023-11-03 | $300.84M 10-Q · filed 2023-11-03 | $373.72M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $15.85M 10-Q · filed 2023-08-08 | $88.73M derived: sum of 3 quarters · filed 2024-02-27 | $88.79M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $14.72M 10-Q · filed 2023-05-09 | $87.60M derived: sum of 2 quarters · filed 2024-02-27 | $87.66M derived: sum of 3 quarters · filed 2024-02-27 | $88.85M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $72.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $72.94M derived: sum of 2 quarters · filed 2024-02-27 | $74.13M derived: sum of 3 quarters · filed 2024-02-27 | $281.95M 10-K · filed 2024-02-27 |
| 2021-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.25M derived: sum of 2 quarters · filed 2022-11-08 | $209.07M 10-Q · filed 2022-11-08 | $338.45M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $209.00M 10-Q · filed 2022-08-04 | $338.38M derived: sum of 3 quarters · filed 2023-02-28 | $337.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $207.81M 10-Q · filed 2022-05-05 | $337.19M derived: sum of 2 quarters · filed 2023-02-28 | $336.76M derived: sum of 3 quarters · filed 2023-02-28 | $337.07M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $129.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $128.94M derived: sum of 2 quarters · filed 2023-02-28 | $129.25M derived: sum of 3 quarters · filed 2023-02-28 | $298.14M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$437.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$128.00K derived: sum of 2 quarters · filed 2021-11-04 | $168.76M 10-Q · filed 2021-11-04 | $261.72M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $309.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $169.20M 10-Q · filed 2021-08-05 | $262.16M derived: sum of 3 quarters · filed 2022-02-22 | $262.14M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $168.89M 10-Q · filed 2021-05-06 | $261.85M derived: sum of 2 quarters · filed 2022-02-22 | $261.83M derived: sum of 3 quarters · filed 2022-02-22 | $262.00M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $92.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $92.94M derived: sum of 2 quarters · filed 2022-02-22 | $93.10M derived: sum of 3 quarters · filed 2022-02-22 | $93.10M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $148.00K derived: sum of 2 quarters · filed 2020-11-05 | $148.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $168.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $61.59M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |